MBC Advocate· @MBCadvocate · X·· 1 天前评分70
正文 · 机器翻译
postMONARCH III期试验中，abemaciclib联合fulvestrant与安慰剂联合fulvestrant相比，用于既往CDK4/6抑制剂联合内分泌治疗后出现进展的HR+、HER2-晚期乳腺癌的总生存期。$AZN $LLY #ESMO26 #BCAM https://www.annalsofoncology.org/article/S0923-7534%2826%2908075-0/fulltext
72 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
1RO按 Rapid oral 1: Breast cancer, advanced stage 对上
Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
https://esmocongress.esmo.org来源：MBC Advocate · x.com